Topiramate: Uses, Dosage & Side Effects
Anticonvulsant used for epilepsy and migraine prevention
Quick facts about Topiramate
Key Takeaways
- Dual indication: Topiramate treats epileptic seizures (monotherapy or adjunctive) and prevents migraine headaches in adults
- Pregnancy warning: Must not be used during pregnancy for migraine prevention; only for epilepsy if no alternative exists. Highly effective contraception is mandatory
- Gradual dose titration: Always start at a low dose and increase slowly to minimise side effects such as cognitive impairment and tingling
- Weight loss is common: Topiramate frequently causes weight loss – monitor weight regularly, especially in children
- Never stop suddenly: Abrupt discontinuation can trigger seizures; always taper under medical supervision
What Is Topiramate and What Is It Used For?
Topiramate is an anticonvulsant (antiepileptic) medication belonging to the group of sulfamate-substituted monosaccharides. It is prescribed for three primary indications: monotherapy for epileptic seizures in adults and children over 6 years, adjunctive therapy for epileptic seizures in adults and children aged 2 and older, and the prevention of migraine headaches in adults.
Topiramate works through multiple pharmacological mechanisms that distinguish it from other antiepileptic drugs. It blocks voltage-dependent sodium channels, which reduces the abnormal electrical activity in the brain that causes seizures. Additionally, it enhances the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) at certain receptor subtypes, provides antagonism at glutamate receptors (specifically the AMPA/kainate subtype), and inhibits carbonic anhydrase isoenzymes II and IV. This multi-modal mechanism of action contributes to its effectiveness across different seizure types and its prophylactic activity against migraine.
The medication was first approved by the U.S. Food and Drug Administration (FDA) in 1996 and has since been approved by regulatory authorities worldwide, including the European Medicines Agency (EMA). Topiramate is included on the WHO Model List of Essential Medicines, recognising its importance in global healthcare for the treatment of epilepsy. It is marketed under several brand names internationally, with Topamax being the original innovator brand manufactured by Janssen Pharmaceuticals.
Epilepsy
In epilepsy management, topiramate may be used as a single-agent (monotherapy) treatment for adults and children aged 6 years and older with newly diagnosed or recently diagnosed epilepsy. It is effective against both partial-onset seizures (also called focal seizures) and primary generalised tonic-clonic seizures. As adjunctive (add-on) therapy, it can be prescribed alongside other antiepileptic drugs for adults and children as young as 2 years old who have inadequate seizure control with their current medication regimen.
Clinical trials have demonstrated that topiramate significantly reduces seizure frequency when used as add-on therapy, with Cochrane systematic reviews confirming its efficacy across multiple seizure types. The medication has shown particular benefit in patients with drug-resistant epilepsy, where it can be combined with other antiepileptic medications to achieve better seizure control.
Migraine Prevention
For migraine prevention (prophylaxis), topiramate is prescribed to adults who experience frequent migraine attacks – typically four or more migraine days per month. It is important to note that topiramate is used for the prevention of migraine, not for the acute treatment of migraine attacks once they have started. Clinical studies have shown that topiramate can reduce migraine frequency by approximately 50% in a significant proportion of patients, with benefits typically becoming apparent after 4 to 8 weeks at the therapeutic dose.
The National Institute for Health and Care Excellence (NICE) in the UK and similar guideline bodies internationally recognise topiramate as one of the first-line options for migraine prophylaxis, alongside propranolol and amitriptyline. The choice between these options depends on individual patient factors, including comorbid conditions, side effect profile tolerance, and contraindications.
What Should You Know Before Taking Topiramate?
Before starting topiramate, it is essential to discuss your complete medical history with your doctor, including any kidney problems, liver disease, eye conditions (especially glaucoma), or metabolic disorders. Women of childbearing potential must use highly effective contraception due to the significant risk of birth defects.
Contraindications
You must not take topiramate if you are allergic to topiramate or any of the other ingredients in the tablets. For migraine prevention specifically, topiramate is absolutely contraindicated during pregnancy and in women of childbearing potential who are not using highly effective contraception. For epilepsy treatment, it must not be used during pregnancy unless it is the only treatment that provides adequate seizure control.
Topiramate can cause serious birth defects. Among women taking topiramate during pregnancy, approximately 4 to 9 babies out of 100 are born with congenital malformations, compared to 1 to 3 out of 100 in women not taking antiepileptic drugs. Common defects include cleft lip, cleft palate, and hypospadias in boys. There is also a 2- to 3-fold increased risk of autism spectrum disorder, intellectual disability, and ADHD in exposed children.
Warnings and Precautions
Speak to your doctor before taking topiramate if you have any of the following conditions, as your treatment may need to be adjusted or additional monitoring may be required:
- Kidney problems: Particularly kidney stones or if you are undergoing dialysis. Topiramate can increase the risk of kidney stone formation due to its carbonic anhydrase inhibitory effects. Drinking plenty of fluids throughout the day can help reduce this risk
- Metabolic acidosis: A history of abnormalities in blood chemistry or body fluids, including acidosis. Topiramate may worsen or cause metabolic acidosis, which can lead to symptoms such as rapid breathing, fatigue, and loss of appetite
- Liver problems: Hepatic impairment may affect how the drug is metabolised and may require dose adjustments
- Eye problems: Particularly glaucoma. Topiramate has been associated with acute myopia and secondary angle-closure glaucoma, which can occur within the first month of treatment and requires immediate medical attention
- Growth concerns in children: Weight monitoring is essential as topiramate frequently causes weight loss, which may affect growth in paediatric patients
- Ketogenic diet: If you are on a high-fat, low-carbohydrate diet, the combination with topiramate may increase the risk of kidney stones and metabolic acidosis
A small number of people treated with antiepileptic medications, including topiramate, have experienced thoughts of self-harm or suicide. If you ever develop such thoughts, contact your doctor immediately. Do not stop the medication on your own – sudden discontinuation can be dangerous.
Topiramate can cause decreased sweating (oligohidrosis), particularly in children. This can lead to dangerously elevated body temperature (hyperthermia) in hot weather or during vigorous physical activity. Adequate hydration and avoidance of excessive heat are important precautions.
In rare cases, topiramate can cause elevated ammonia levels in the blood (hyperammonaemia), particularly when used in combination with valproic acid (sodium valproate). This can lead to altered brain function (encephalopathy). Symptoms include difficulty thinking, remembering, or problem-solving; reduced alertness; and excessive drowsiness with low energy. These symptoms require immediate medical attention.
Severe skin reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported rarely with topiramate use. If you develop a skin rash, blisters, or sores in the mouth, throat, nose, eyes, or genital area, stop taking the medication and seek immediate medical care.
Pregnancy and Breastfeeding
The use of topiramate during pregnancy requires extremely careful consideration due to the well-documented risks to the developing foetus. Regulatory agencies including the EMA and FDA have issued strong warnings about prenatal topiramate exposure.
Risks of topiramate during pregnancy
- Birth defects: Approximately 4–9 out of 100 babies born to mothers taking topiramate have congenital malformations, compared to 1–3 out of 100 in the general population. The most frequently observed defects are cleft lip, cleft palate, and hypospadias (a penile malformation in boys). These malformations can develop very early in pregnancy, before the woman may know she is pregnant
- Neurodevelopmental effects: Children exposed to topiramate in utero may have a 2- to 3-fold increased risk of autism spectrum disorder, intellectual disability, and attention deficit hyperactivity disorder (ADHD) compared to children born to women with epilepsy not taking antiepileptic drugs
- Small for gestational age: In one study, 18% of infants born to mothers taking topiramate were smaller than expected at birth, compared to 5% in the general non-epileptic population
Contraceptive requirements
Women of childbearing potential must use highly effective contraception during topiramate treatment and for at least 4 weeks after the last dose. Options include:
- A highly effective non-hormonal method, such as a copper intrauterine device (IUD)
- A hormonal intrauterine system (IUS)
- Two complementary methods: a hormonal method (such as oral contraceptives) combined with a barrier method (such as condoms or diaphragm) – this combination is necessary because topiramate can reduce the effectiveness of hormonal contraceptives
A pregnancy test should be performed before starting treatment. Women should consult their doctor at least once a year to review their treatment and discuss the ongoing risks.
Breastfeeding
Topiramate passes into breast milk. Effects observed in breastfed infants of treated mothers include diarrhoea, drowsiness, irritability, and poor weight gain. Your doctor will weigh the benefits of treatment for you against the potential risks to the infant. If you breastfeed while taking topiramate, inform your doctor immediately if the infant shows any unusual symptoms.
Driving and Operating Machinery
Dizziness, fatigue, and visual disturbances may occur during topiramate treatment. Do not drive or operate machinery until you know how the medication affects you. You are personally responsible for assessing whether you are fit to drive or perform tasks requiring alertness.
How Does Topiramate Interact with Other Drugs?
Topiramate interacts with numerous medications. Most significantly, it can reduce the effectiveness of hormonal contraceptives, increase lithium levels, and interact with other antiepileptic drugs. Always inform your doctor about all medications you are taking, including herbal supplements.
Drug interactions with topiramate can be broadly categorised into pharmacokinetic interactions (where one drug affects the blood levels of another) and pharmacodynamic interactions (where drugs have additive or opposing effects). Understanding these interactions is crucial for safe and effective treatment.
Major Interactions
The following interactions are considered clinically significant and may require dose adjustments or alternative medications:
| Drug | Effect | Clinical Recommendation |
|---|---|---|
| Hormonal contraceptives | Topiramate reduces effectiveness of oral contraceptives | Add barrier method (condom/diaphragm); report any menstrual changes |
| Valproic acid / Sodium valproate | Risk of hyperammonaemia and encephalopathy; both drugs may have altered levels | Monitor ammonia levels; watch for cognitive changes |
| Phenytoin | Phenytoin levels may increase; topiramate levels may decrease | Monitor phenytoin levels; may need topiramate dose adjustment |
| Carbamazepine | Carbamazepine reduces topiramate levels by up to 40% | May need higher topiramate dose; monitor seizure control |
| Lithium | Topiramate may alter lithium blood levels | Monitor lithium levels closely when starting or adjusting topiramate |
| Metformin | Topiramate may alter metformin clearance and increase lactic acidosis risk | Monitor blood glucose; watch for signs of lactic acidosis |
Other Notable Interactions
The following drug interactions should also be discussed with your doctor:
- CNS depressants (sedatives, muscle relaxants, benzodiazepines, opioids): Additive cognitive impairment, drowsiness, and reduced coordination. Use caution and avoid alcohol
- Hydrochlorothiazide: May increase topiramate levels. Monitor for increased side effects
- Digoxin: Topiramate may reduce digoxin levels. Monitor digoxin blood concentrations
- Risperidone: Topiramate may reduce risperidone exposure. Monitor clinical response
- Amitriptyline: Topiramate may increase amitriptyline levels. Watch for increased side effects
- Haloperidol: Potential interaction affecting haloperidol levels
- Propranolol: Potential pharmacokinetic interaction
- Diltiazem: May affect topiramate or diltiazem metabolism
- Venlafaxine: Potential interaction; clinical significance under investigation
- Flunarizine: May increase topiramate exposure or vice versa
- Pioglitazone / Glibenclamide: Topiramate may affect blood glucose control in diabetic patients
- Warfarin: Topiramate may alter the anticoagulant effect. Monitor INR closely
- St John’s Wort (Hypericum perforatum): This herbal supplement may reduce topiramate levels through enzyme induction
Maintain a complete list of all medications, supplements, and herbal products you take. Show this list to your doctor and pharmacist before starting any new treatment. This helps prevent potentially dangerous interactions.
Food and Drink
Topiramate can be taken with or without food. Drink plenty of fluids throughout the day to help prevent kidney stone formation. Avoid alcohol during treatment, as it can worsen side effects such as drowsiness, dizziness, and cognitive impairment.
What Is the Correct Dosage of Topiramate?
Topiramate dosing follows a gradual titration schedule, starting at a low dose (typically 25 mg once or twice daily) and increasing over several weeks. The target dose depends on the indication: 100–200 mg/day for migraine prevention and up to 400 mg/day for epilepsy in adults. Your doctor will determine the optimal dose for you.
The dosage of topiramate varies according to the indication (epilepsy or migraine), whether it is used as monotherapy or adjunctive therapy, and the patient’s age and body weight. The general principle is to start with a low dose and increase it gradually (titrate) to minimise side effects and find the lowest effective dose.
Adults
Epilepsy – Monotherapy
Start with 25 mg once daily in the evening for the first week. Increase by 25–50 mg per week. The recommended target dose is 100–200 mg/day, divided into two doses. The maximum recommended dose is 500 mg/day, but doses above 400 mg/day have not been shown to provide additional benefit in most patients.
Epilepsy – Adjunctive Therapy
Start with 25–50 mg once daily in the evening for the first week. Increase by 25–50 mg per week. The usual effective dose is 200–400 mg/day, divided into two doses. Some patients may require up to 800 mg/day, though this should be guided by clinical response and tolerability.
Migraine Prevention
Start with 25 mg once daily in the evening for the first week. Increase by 25 mg per week. The recommended target dose is 100 mg/day, divided into two doses (50 mg twice daily). Some patients may benefit from a total daily dose of 50 mg or 200 mg, depending on individual response.
Children
Epilepsy – Children aged 6 and older (Monotherapy)
Start with 0.5–1 mg/kg bodyweight per day in the evening. Increase by 0.5–1 mg/kg per week. The recommended target dose is 100–400 mg/day (or approximately 3–6 mg/kg/day), depending on clinical response.
Epilepsy – Children aged 2 and older (Adjunctive Therapy)
Start with 25 mg (or 1–3 mg/kg) once daily in the evening. Increase by 1–3 mg/kg per week. The recommended target dose is 5–9 mg/kg/day, divided into two doses.
Important for parents and caregivers: Treatment in girls and women of childbearing potential should be initiated and supervised by a physician experienced in managing epilepsy or migraine. Medical reviews should occur at least once a year. Contact the treating doctor immediately when a girl taking topiramate experiences her first menstrual period, as counselling about contraception and pregnancy risks is essential.
Elderly Patients
No specific dosage adjustment is typically required for elderly patients with normal kidney function. However, since kidney function tends to decline with age, careful monitoring is advisable and slower dose titration may be appropriate. Elderly patients may also be more susceptible to cognitive side effects.
Patients with Kidney Impairment
Topiramate is primarily excreted by the kidneys. In patients with moderate to severe kidney impairment, topiramate clearance is reduced, so lower doses may be needed and the titration should proceed more slowly. Topiramate is removed by haemodialysis, and a supplemental dose may be needed after dialysis sessions.
Missed Dose
If you forget to take a dose, take it as soon as you remember. If it is close to the time for your next dose, skip the missed dose and continue with your regular schedule. If you miss two or more doses in a row, contact your doctor for guidance. Do not take a double dose to make up for a missed one.
Overdose
If you take more topiramate than prescribed, or if a child accidentally ingests the medication, seek immediate medical attention or contact a poison control centre. Take the medication packaging with you.
Symptoms of overdose may include drowsiness, fatigue, reduced alertness, lack of coordination, speech and concentration difficulties, double or blurred vision, dizziness due to low blood pressure, depression or agitation, abdominal pain, and seizures. There is no specific antidote; treatment is supportive. Haemodialysis can effectively remove topiramate from the blood.
What Are the Side Effects of Topiramate?
Like all medications, topiramate can cause side effects. The most common include tingling or numbness, drowsiness, dizziness, nausea, diarrhoea, weight loss, and depression. Many side effects are dose-dependent and may improve with dose reduction. Seek immediate medical attention for signs of metabolic acidosis, severe eye problems, or skin reactions.
Side effects of topiramate vary in frequency and severity. Most are mild to moderate and often improve as the body adjusts to the medication. The gradual dose titration (slow increase in dose) is specifically designed to minimise the occurrence and severity of side effects. Below is a comprehensive overview organised by frequency.
Severe skin rash or blisters, sudden eye pain or vision loss, difficulty breathing, confusion with extreme drowsiness, or thoughts of self-harm.
Very Common (more than 1 in 10 people)
- Depression (new or worsening)
- Tingling, pain, and/or numbness in various body parts (paraesthesia)
- Drowsiness and fatigue
- Dizziness
- Nausea and diarrhoea
- Nasal congestion, runny nose, or sore throat (nasopharyngitis)
- Weight loss
Common (up to 1 in 10 people)
- Anaemia (low red blood cell count)
- Allergic reactions (rash, redness, itching, facial swelling, hives)
- Loss of appetite or decreased appetite
- Anxiety, irritability, mood changes, confusion, disorientation
- Aggression, agitation, anger, abnormal behaviour
- Difficulty falling or staying asleep (insomnia)
- Concentration problems, impaired thinking, memory loss
- Speech difficulties, slurred speech
- Clumsiness, poor coordination, unsteady gait
- Decreased or absent sense of taste
- Involuntary tremor or shaking, rapid uncontrolled eye movements
- Visual disturbances: double vision, blurred vision, reduced acuity
- Vertigo, ringing in the ears, ear pain
- Shortness of breath, cough, nosebleeds
- Vomiting, constipation, abdominal pain, indigestion
- Dry mouth, hair loss, itching
- Joint pain or swelling, muscle cramps, muscle pain or weakness
- Kidney stones, frequent or painful urination
- Fever, feeling unwell, weakness
- Weight gain
Uncommon (up to 1 in 100 people)
- Decreased blood platelets or white blood cells, low potassium
- Elevated liver enzymes, increased eosinophils
- Swollen lymph nodes in neck, armpit, or groin
- Psychosis (hallucinations, severe psychological disturbance)
- Lack of emotion, unusual suspiciousness, panic attacks
- Restlessness, hyperactivity, difficulty reading/writing
- Decreased sweating (dangerous in hot weather, especially in children)
- Metabolic acidosis (rapid breathing, loss of appetite, extreme tiredness)
- Suicidal thoughts or self-harm
- Loss of part of visual field
- Slow or irregular heart rate, palpitations, low blood pressure
- Pancreatitis, bleeding gums, excessive salivation, bad breath
- Excessive thirst, skin discolouration
- Erectile dysfunction, sexual dysfunction
- Blood in urine, urinary incontinence
- Feeling intoxicated, flu-like symptoms
- Cold fingers and toes
Rare (up to 1 in 1,000 people)
- Glaucoma (increased eye pressure with pain and vision loss)
- Hyperammonaemia / hyperammonaemic encephalopathy (high blood ammonia affecting brain function)
- Stevens-Johnson syndrome or toxic epidermal necrolysis (severe skin reactions)
- Liver inflammation (hepatitis) or liver failure
- Blindness in one eye, temporary blindness, night blindness
- Swelling around the eyes
- Raynaud’s phenomenon (colour changes in fingers/toes in cold)
- Loss of consciousness
- Kidney disease
- Uveitis (eye inflammation with redness, pain, light sensitivity) – frequency unknown
- Maculopathy (retinal disease affecting central vision) – frequency unknown
Side Effects in Children
Side effects in children are generally similar to those in adults, but certain effects may be more common in paediatric patients:
- Concentration problems and difficulty with thinking
- Increased acidity in the blood (metabolic acidosis)
- Thoughts of self-harm (more common than in adults)
- Fatigue and drowsiness
- Decreased or increased appetite
- Aggression, abnormal behaviour
- Difficulty sleeping, unsteady gait
- Decreased potassium, emotional blunting
- Watery eyes, slow or irregular heartbeat
- Dizziness, vomiting, fever (common)
- Hyperactivity, feeling hot, learning difficulties (uncommon)
It is important to report suspected side effects after the medication has been authorised. This enables continuous monitoring of the medicine’s benefit-risk balance. Healthcare professionals and patients are encouraged to report suspected adverse reactions to their national pharmacovigilance authority.
How Should You Store Topiramate?
Store topiramate tablets at or below 25°C (77°F) in the original packaging. Keep out of reach of children. Do not use the medicine after the expiry date. Protect from moisture.
Proper storage is important to maintain the effectiveness and safety of your medication. Follow these guidelines:
- Temperature: Store at or below 25°C (77°F). Do not freeze
- Blister packs: Keep in the original packaging to protect from moisture
- Bottles: Keep in the original container with the cap tightly closed. Each bottle contains a desiccant (moisture absorber) – do not swallow the desiccant
- Keep out of the sight and reach of children
- Expiry date: Do not use the medicine after the expiry date stated on the packaging (the expiry date refers to the last day of that month)
- Disposal: Do not dispose of medicines down the drain or in household waste. Ask your pharmacist about proper medication disposal methods. These measures help protect the environment
What Does Topiramate Contain?
Each topiramate tablet contains the active substance topiramate (available in 25, 50, 100, or 200 mg strengths) along with inactive excipients including lactose monohydrate, pregelatinised maize starch, microcrystalline cellulose, sodium starch glycolate, and magnesium stearate. The tablets are film-coated.
Active Ingredient
The active substance is topiramate, a sulfamate-substituted monosaccharide. Each tablet contains 25 mg, 50 mg, 100 mg, or 200 mg of topiramate.
Inactive Ingredients (Excipients)
The inactive ingredients serve various functions in the tablet formulation:
- Tablet core: Lactose monohydrate, pregelatinised maize starch, microcrystalline cellulose, sodium starch glycolate (type A), magnesium stearate
- Film coating: Hypromellose, macrogol, polysorbat 80, with colourants including titanium dioxide (E171, all strengths), yellow iron oxide (E172, 50 mg and 100 mg), red iron oxide (E172, 200 mg), and carnauba wax
Topiramate tablets contain lactose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine. The tablets contain less than 1 mmol (23 mg) sodium per tablet, which is essentially sodium-free.
Tablet Identification
| Strength | Colour | Shape & Size | Imprint |
|---|---|---|---|
| 25 mg | White | Round, 6 mm diameter | “TOP” / “25” |
| 50 mg | Light yellow | Round, 7 mm diameter | “TOP” / “50” |
| 100 mg | Yellow | Round, 9 mm diameter | “TOP” / “100” |
| 200 mg | Salmon pink | Round, 10 mm diameter | “TOP” / “200” |
Available in blister packs (aluminium-aluminium foil) and opaque plastic bottles with sealed lids. Pack sizes include 10, 20, 28, 30, 50, 56, 60, 100, or 200 tablets. Each bottle contains a desiccant that must not be swallowed. Not all pack sizes may be marketed in all countries.
Frequently Asked Questions About Topiramate
Topiramate is an anticonvulsant medication used for three main indications: (1) as monotherapy for epileptic seizures in adults and children over 6 years old, (2) as adjunctive (add-on) therapy for epileptic seizures in adults and children aged 2 years or older, and (3) for the prevention of migraine headaches in adults. It works through multiple mechanisms including blocking sodium channels, enhancing GABA activity, antagonising glutamate receptors, and inhibiting carbonic anhydrase.
Topiramate poses significant risks during pregnancy and strict rules apply. For migraine prevention, it must not be used during pregnancy under any circumstances. For epilepsy, it should only be used during pregnancy if it is the only treatment that adequately controls seizures and no alternatives exist. Studies show that approximately 4–9 out of 100 babies born to women taking topiramate have birth defects. Women of childbearing potential must use highly effective contraception during treatment and for at least 4 weeks after the last dose.
The most common side effects (affecting more than 1 in 10 people) include depression, tingling or numbness in various body parts, drowsiness, fatigue, dizziness, nausea, diarrhoea, nasal congestion or sore throat, and weight loss. Common side effects (affecting up to 1 in 10 people) include anxiety, mood changes, confusion, memory problems, difficulty sleeping, speech difficulties, and kidney stones. These effects are often dose-dependent and may improve with dose reduction or over time as the body adjusts.
Yes, weight loss is a very common side effect of topiramate, affecting more than 1 in 10 users. This is believed to result from reduced appetite and altered taste perception. Weight should be monitored regularly during treatment. If excessive weight loss occurs, or if a child does not gain adequate weight, consult your doctor. The weight-loss effect has led to the use of topiramate in some combination products for weight management in certain countries, though this is not its primary approved indication.
Yes, topiramate can reduce the effectiveness of hormonal contraceptives, including combined oral contraceptive pills. This means that relying solely on hormonal birth control may not provide adequate protection against pregnancy. Women taking topiramate should use either a highly effective non-hormonal method (such as a copper IUD) or combine hormonal contraception with a barrier method (such as condoms). Any changes in menstrual bleeding patterns should be reported to your doctor immediately.
Topiramate is typically started at a low dose and gradually increased over several weeks. For epilepsy, some improvement in seizure control may be noticed within the first few weeks, but the full benefit usually takes 2–4 weeks at the target dose to become apparent. For migraine prevention, it generally takes 4–8 weeks at the therapeutic dose (usually 100 mg/day) before a meaningful reduction in migraine frequency is observed. The slow dose titration is essential to minimise side effects.
No, you should never stop taking topiramate abruptly without medical guidance. Sudden discontinuation can cause seizures to return or worsen, even if you are taking the medication for migraine prevention rather than epilepsy. If your doctor decides to stop your treatment, the dose will be gradually reduced over several days to weeks. This tapering approach allows your body to adjust safely. If you have missed two or more consecutive doses, contact your doctor for advice before resuming the medication.
References
This article is based on the following peer-reviewed and authoritative medical sources. All information has been reviewed according to international medical standards and evidence level 1A principles.
- European Medicines Agency (EMA). Topiramate – Summary of Product Characteristics. EMA, 2024. Available at: ema.europa.eu
- U.S. Food and Drug Administration (FDA). Topamax (topiramate) – Prescribing Information. FDA, 2024.
- Cochrane Database of Systematic Reviews. Topiramate add-on therapy for drug-resistant focal epilepsy. Cochrane Library, 2023. doi:10.1002/14651858.CD001417.pub4
- Cochrane Database of Systematic Reviews. Topiramate for the prophylaxis of episodic migraine in adults. Cochrane Library, 2023.
- National Institute for Health and Care Excellence (NICE). Epilepsies in children, young people and adults (NG217). NICE, 2024. Available at: nice.org.uk
- National Institute for Health and Care Excellence (NICE). Headaches in over 12s: diagnosis and management (CG150). NICE, 2021.
- World Health Organization (WHO). WHO Model List of Essential Medicines, 23rd List. WHO, 2023. Available at: who.int
- British National Formulary (BNF). Topiramate. BNF, 2025. Available at: bnf.nice.org.uk
- Marson AG, et al. The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy. Lancet. 2021;397(10282):1375-1386.
- Silberstein SD, et al. Practice parameter: Evidence-based guidelines for migraine headache. Neurology. 2012;78(17):1337-1345.
About This Article
This article was written and medically reviewed by the iMedic Medical Editorial Team, consisting of licensed specialist physicians in neurology, clinical pharmacology, and internal medicine.
Content reviewed by board-certified physicians specialising in neurology and clinical pharmacology, following WHO, EMA, FDA, and NICE guidelines. Evidence level 1A (systematic reviews and meta-analyses of randomised controlled trials).
All drug information is based on approved prescribing information, peer-reviewed clinical evidence, and international guidelines. No pharmaceutical industry funding or commercial sponsorship. Reviewed using the GRADE evidence framework.
Publication date: | Last medical review: | Next scheduled review: